Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188. doi: 10.3760/cma.j.issn.1001-0939.2020.03.009.
At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.
2019年12月底，一种新型冠状病毒（COVID-19）在武汉引发疫情，并迅速蔓延至中国各省及全球其他26个国家，导致疫情防控形势严峻。目前尚无特效药物。既往研究表明，磷酸氯喹（氯喹）具有广泛的抗病毒作用，包括抗冠状病毒。我们发现，使用氯喹治疗新型冠状病毒肺炎确诊患者可能提高治疗成功率，缩短住院时间并改善患者预后。为指导和规范氯喹在新型冠状病毒肺炎患者中的使用，广东省科学技术厅和广东省卫生健康委员会氯喹治疗新型冠状病毒肺炎多中心协作组经广泛讨论制定本专家共识。对于确诊为新型冠状病毒肺炎轻、中、重型且无氯喹禁忌证的患者，推荐使用磷酸氯喹片，每日2次，每次500mg，疗程10天。
